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Scaling up multidrug-resistant tuberculosis care in China
Drug-resistant tuberculosis threatens to undermine 
advances in tuberculosis control worldwide. Multidrug-
resistant tuberculosis (MDRTB), deﬁ ned as resistance 
to isoniazid and rifampicin, requires treatment for 
up to 24 months with expensive diagnostics and 
second-line drugs. Fewer than 15% of patients 
diagnosed with tuberculosis worldwide receive drug 
susceptibility testing (DST); only 20% of the estimated 
480 000 new cases of MDRTB annually are treated 
appropriately.1 Of these, cure rarely exceeds 65%. 
Those on ineﬀ ective therapy risk acquiring additional 
resistance and spreading drug-resistant tuberculosis 
to others. In recent years, new molecular diagnostics 
and antituberculosis drugs promise an opportunity 
to improve outcomes for patients with drug-resistant 
tuberculosis, leading the WHO to prioritise universal 
access to prevention, diagnosis, and treatment of 
MDRTB.1 However, identiﬁ cation of viable models for 
coordinating and ﬁ nancing scale-up of such services 
remains a major challenge for most middle-income and 
low-income countries. 
After the widespread implementation of directly 
observed therapy, short course (DOTS), tuberculosis 
prevalence and mortality have decreased greatly in China.2 
However, MDRTB remains a formidable problem for 
China with an estimated 100 000 incident cases annually, 
a ﬁ fth of the global burden.3 In The Lancet Global Health, 
Renzhong Li and colleagues report4 on an intervention to 
provide a comprehensive programme of universal access 
to MDRTB care, which might oﬀ er a model of improved 
care for other high-burden countries. The programme 
was implemented in four cities and involved provision of 
a comprehensive diagnostic, care, and ﬁ nancial package, 
including ﬁ nancing for specimen shipment, resistance 
testing, costs of patient transportation and nutritional 
supplements, and a subsidy for directly observed therapy. 
It emphasised close communication between treatment 
facilities and improved care linkages. Diagnosis consisted 
of the use of a rapid molecular diagnostic (Genechip 
Capitabio) for isoniazid and rifampicin DST and training 
of centralised staﬀ  in molecular and conventional 
DST. Treatment was tailored to conﬁ rmed degree of 
tuberculosis resistance, per WHO guidelines. The ﬁ nancial 
scheme imposed a cap of US$4644 per treated case, with 
patients’ expenses capped at 10% of the total, through 
creative use of government insurance funds and project 
resources. The results were impressive,4 with a 90% 
decrease in time from testing to treatment initiation 
and substantial increases in the number of diagnosed 
patients, use of appropriate regimen, and retention at 
6 months, largely due to major decreases in deaths and 
defaults. 
The ﬁ ndings from Li and colleagues4 add to 
the mounting evidence that the prioritisation of 
investments in operational coordination improvements 
is crucial for better outcomes of MDRTB.4–6 Speciﬁ cally, 
they show that a faster time to diagnosis has both 
clinical and cost beneﬁ ts: elimination of hospital 
stay preceding diagnosis, which reduces potential 
nosocomial transmission of MDRTB along with hospital 
expenses, and faster initiation of MDRTB treatment. 
The investigators note that the National Center for 
Tuberculosis Control and Prevention will scale-up 
features of the programme nationwide, including free 
testing for MDRTB with molecular diagnostics and the 
standard care package for MDRTB. This investment 
would seem to be wise. An estimate of the national 
scale-up cost suggests an initial price tag of $500 million 
annually, or roughly double domestic spending on 
tuberculosis in 2011.7 This number is a substantial ﬁ gure, 
but only about 0·2% of annual public health spending 
in China (an amount considered low by international 
standards) and 80% of the government’s yearly outlay 
on HIV.8–10 Moreover, extrapolating the mortality eﬀ ect 
shown in Li and colleagues’ study,4 MDRTB-related 
deaths could be reduced by roughly 80%, with up to 
20 000 deaths averted in the ﬁ rst year alone.
To maximise the chances of success, additional 
elements of the programme should be considered. The 
molecular diagnostic used in the study’s package4 only 
performs on smear-positive tuberculosis cases, which 
were just 28% of those diagnosed with tuberculosis. A 
molecular diagnostic such as Xpert MTB/RIF (Cepheid) 
or MTBDRplus (Hain Lifescience GmbH), which can be 
done on smear-negative or culture-positive specimens, 
could be incorporated to capture all MDRTB cases and 
avoid initiating patients with smear-negative samples 
on ineﬀ ective therapy.11 47 (29%) of the 163 patients 
with MDRTB tested for additional drug resistance had 
extensively (XDR) or pre-XDR tuberculosis discovered a 
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median of 45–55 days after start of MDRTB treatment, 
delaying initiation of an eﬀ ective regimen. As rapid 
second-line DSTs become available, they should be 
incorporated into diagnostic schemes to ensure the 
most eﬀ ective treatment for all patients. Further 
beneﬁ ts could be gained from integrating HIV testing 
and treatment, as the authors acknowledge.4 
Comprehensive, high-quality treatment models are 
challenging logistically and ﬁ nancially, demanding 
commitment at all levels and implementers with 
considerable technical expertise. This study oﬀ ers a model 
with potential for achieving advances in tuberculosis 
treatment relatively swiftly, while highlighting important 
policy issues that merit attention. As improved 
diagnostics and drugs for MDRTB become available, the 
relevance of such a complete, integrated approach to 
diagnosis, treatment, and cost to scale-up MDRTB care 
will only continue to grow.
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